Vandetanib

Vandetanib

CAT N°: 14706
Price:

From €55.00 €46.75

Vandetanib is a multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFR?, Tie-2, and FGFR1 in cell-free assays (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively).{53195,24156} It also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM). Vandetanib (1 and 2.5 µM) induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells.{53196} It inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells, as well as human umbilical vein endothelial cells (HUVECs), with IC50 values of 10, 8.1, 9.4, and 7.1 µM, respectively.{53197} Vandetanib (200 mg/kg) increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model.{53198} It reduces tumor growth in a variety of mouse xenograft models, including lung, colon, and breast cancer models, when administered at doses of 25, 50, and 100 mg/kg per day.{53195} Formulations containing vandetanib have been used in the treatment of medullary thyroid cancer.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • N-(4-bromo-2-fluorophenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl)methoxy]-4-quinazolinamine
  • Correlated keywords
    • 338992-00-0 660412-36-2 CH331 ZD6474 CH-331 ZD-6474 inhibitors kinases angiogenesis cancers signals transductions intracellular signaling broad spectrum inhibits inhibitions tyrosine vascular endothelial growth factor VEGFRs epidermal EGFR cells growth metastasis proteins ZDs CHs non-receptor ABL RET SRC serine/threonine serine threonine Caprelsa multikinase
  • Product Overview:
    Vandetanib is a multi-kinase inhibitor that inhibits VEGFR2, VEGFR3, VEGFR1, EGFR, PDGFR?, Tie-2, and FGFR1 in cell-free assays (IC50s = 40, 110, 1,600, 500, 1,100, 2,500, and 3,600 nM, respectively).{53195,24156} It also binds to 142 additional kinases in a panel of 442 kinases (Kds = 4.6-7,900 nM). Vandetanib (1 and 2.5 µM) induces apoptosis and cell cycle arrest at the G0/G1 phase in GEO colon and OVCAR-3 ovarian cancer cells.{53196} It inhibits proliferation of HAK1-B, KYN-2, and Huh7 hepatocarcinoma cells, as well as human umbilical vein endothelial cells (HUVECs), with IC50 values of 10, 8.1, 9.4, and 7.1 µM, respectively.{53197} Vandetanib (200 mg/kg) increases survival and decreases tumor angiogenesis and VEGFR2 levels in a D54MG glioblastoma mouse xenograft model.{53198} It reduces tumor growth in a variety of mouse xenograft models, including lung, colon, and breast cancer models, when administered at doses of 25, 50, and 100 mg/kg per day.{53195} Formulations containing vandetanib have been used in the treatment of medullary thyroid cancer.

We also advise you

Any project? Any challenge? We are in!
Contact us

Headquarters:
Parc d’activités du Pas du Lac
10 bis avenue Ampère

78180 Montigny le Bretonneux
France

Call us
Information
My account
Follow us

Copyright © 2024 BERTIN BIOREAGENT. All rights reserved | Terms & conditions

Secure payment
Subscribe to our newsletter